Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

25,966 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sex disparities and neutralizing antibody durability to SARS-CoV-2 infection in convalescent individuals.
Markmann AJ, Giallourou N, Bhowmik DR, Hou YJ, Lerner A, Martinez DR, Premkumar L, Root H, van Duin D, Napravnik S, Graham SD, Guerra Q, Raut R, Petropoulos CJ, Wrin T, Cornaby C, Schmitz J, Kuruc J, Weiss S, Park Y, Baric R, de Silva AM, Margolis DM, Bartelt LA. Markmann AJ, et al. Among authors: park y. medRxiv [Preprint]. 2021 Feb 3:2021.02.01.21250493. doi: 10.1101/2021.02.01.21250493. medRxiv. 2021. PMID: 33564775 Free PMC article. Updated. Preprint.
The RBD Of The Spike Protein Of SARS-Group Coronaviruses Is A Highly Specific Target Of SARS-CoV-2 Antibodies But Not Other Pathogenic Human and Animal Coronavirus Antibodies.
Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann A, Cornaby C, Bartelt L, Weiss S, Park Y, Edwards CE, Weimer E, Scherer EM, Roupael N, Edupuganti S, Weiskopf D, Tse LV, Hou YJ, Margolis D, Sette A, Collins MH, Schmitz J, Baric RS, de Silva AM. Premkumar L, et al. Among authors: park y. medRxiv [Preprint]. 2020 May 10:2020.05.06.20093377. doi: 10.1101/2020.05.06.20093377. medRxiv. 2020. PMID: 32511572 Free PMC article. Updated. Preprint.
Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals.
Markmann AJ, Giallourou N, Bhowmik DR, Hou YJ, Lerner A, Martinez DR, Premkumar L, Root H, van Duin D, Napravnik S, Graham SD, Guerra Q, Raut R, Petropoulos CJ, Wrin T, Cornaby C, Schmitz J, Kuruc J, Weiss S, Park Y, Baric R, de Silva AM, Margolis DM, Bartelt LA. Markmann AJ, et al. Among authors: park y. mSphere. 2021 Aug 25;6(4):e0027521. doi: 10.1128/mSphere.00275-21. Epub 2021 Aug 25. mSphere. 2021. PMID: 34431693 Free PMC article.
Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study.
Bartelt LA, Markmann AJ, Nelson B, Keys J, Root H, Henderson HI, Kuruc J, Baker C, Bhowmik DR, Hou YJ, Premkumar L, Cornaby C, Schmitz JL, Weiss S, Park Y, Baric R, de Silva AM, Lachiewicz A, Napravnik S, van Duin D, Margolis DM. Bartelt LA, et al. Among authors: park y. mBio. 2022 Oct 26;13(5):e0175122. doi: 10.1128/mbio.01751-22. Epub 2022 Sep 22. mBio. 2022. PMID: 36135380 Free PMC article. Clinical Trial.
Erratum for Markmann et al., "Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals".
Markmann AJ, Giallourou N, Bhowmik DR, Hou YJ, Lerner A, Martinez DR, Premkumar L, Root H, van Duin D, Napravnik S, Graham SD, Guerra Q, Raut R, Petropoulos CJ, Wrin T, Cornaby C, Schmitz J, Kuruc J, Weiss S, Park Y, Baric R, de Silva AM, Margolis DM, Bartelt LA. Markmann AJ, et al. Among authors: park y. mSphere. 2021 Oct 27;6(5):e0073621. doi: 10.1128/mSphere.00736-21. Epub 2021 Sep 8. mSphere. 2021. PMID: 34494885 Free PMC article. No abstract available.
The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients.
Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann A, Cornaby C, Bartelt L, Weiss S, Park Y, Edwards CE, Weimer E, Scherer EM, Rouphael N, Edupuganti S, Weiskopf D, Tse LV, Hou YJ, Margolis D, Sette A, Collins MH, Schmitz J, Baric RS, de Silva AM. Premkumar L, et al. Among authors: park y. Sci Immunol. 2020 Jun 11;5(48):eabc8413. doi: 10.1126/sciimmunol.abc8413. Sci Immunol. 2020. PMID: 32527802 Free PMC article.
Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial.
Hurvitz SA, Kim SB, Chung WP, Im SA, Park YH, Hegg R, Kim MH, Tseng LM, Petry V, Chung CF, Iwata H, Hamilton E, Curigliano G, Xu B, Egorov A, Liu Y, Cathcart J, Bako E, Tecson K, Verma S, Cortés J. Hurvitz SA, et al. Among authors: park yh. ESMO Open. 2024 May;9(5):102924. doi: 10.1016/j.esmoop.2024.102924. Epub 2024 Apr 24. ESMO Open. 2024. PMID: 38796287 Clinical Trial.
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer.
Park KH, Loibl S, Sohn J, Park YH, Jiang Z, Tadjoedin H, Nag S, Saji S, Md Yusof M, Villegas EMB, Lim EH, Lu YS, Ithimakin S, Tseng LM, Dejthevaporn T, Chen TW, Lee SC, Galvez C, Malwinder S, Kogawa T, Bajpai J, Brahma B, Wang S, Curigliano G, Yoshino T, Kim SB, Pentheroudakis G, Im SA, Andre F, Ahn JB, Harbeck N. Park KH, et al. Among authors: park yh. ESMO Open. 2024 May;9(5):102974. doi: 10.1016/j.esmoop.2024.102974. Epub 2024 Apr 12. ESMO Open. 2024. PMID: 38796284
25,966 results
You have reached the last available page of results. Please see the User Guide for more information.